Target therapy in metastatic renal cell carcinoma

G. Cartenì, A. M. Grimaldi, T. Guida, F. Riccardi, M. Biglietto, E. Perrotta, M. Otero, P. De Rosa, G. Nicolella, G. Esposito, R. Fiorentino, B. Chiurazzi, C. Battista, N. Panza

Research output: Contribution to journalArticle

Abstract

Metastatic RCC with 38,000 new cases diagnosed in the United States every year is notoriously resistant to conventional chemotherapy and is almost invariably an incurable condition. New biologic drugs are beginning to break this resistance, reflecting in the registration of four innovative agents for treatment of advanced RCC in the last 2 years, bevacizumab, sorafenib, sunitinib and temsirolimus. Small-molecule multikinase inhibitors targeting VEGF receptors (sunitinib and sorafenib) can prolong time to progression and preserve quality of life when used in newly diagnosed or previously treated patients. The anti-VEGF antibody bevacizumab enhances response rate and prolongs disease control when added to interferon. Temsirolimus, mammalian target of rapamycin inhibitor, prolongs the survival duration of patients with poor-risk disease. In this review, we report pre-clinical data, data relative to registrative phase III trials, and guideline indications for an optimal use of these new agents that are revolutionising the management of metastatic Renal Cell Carcinoma.

Original languageEnglish
Pages (from-to)38-41
Number of pages4
JournalEuropean Journal of Cancer, Supplement
Volume6
Issue number14
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor Receptor
Sirolimus
Interferons
Vascular Endothelial Growth Factor A
Anti-Idiotypic Antibodies
Quality of Life
Guidelines
Drug Therapy
Survival
Therapeutics
Pharmaceutical Preparations
sunitinib
sorafenib
temsirolimus
Bevacizumab

Keywords

  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cartenì, G., Grimaldi, A. M., Guida, T., Riccardi, F., Biglietto, M., Perrotta, E., ... Panza, N. (2008). Target therapy in metastatic renal cell carcinoma. European Journal of Cancer, Supplement, 6(14), 38-41. https://doi.org/10.1016/j.ejcsup.2008.06.022

Target therapy in metastatic renal cell carcinoma. / Cartenì, G.; Grimaldi, A. M.; Guida, T.; Riccardi, F.; Biglietto, M.; Perrotta, E.; Otero, M.; De Rosa, P.; Nicolella, G.; Esposito, G.; Fiorentino, R.; Chiurazzi, B.; Battista, C.; Panza, N.

In: European Journal of Cancer, Supplement, Vol. 6, No. 14, 10.2008, p. 38-41.

Research output: Contribution to journalArticle

Cartenì, G, Grimaldi, AM, Guida, T, Riccardi, F, Biglietto, M, Perrotta, E, Otero, M, De Rosa, P, Nicolella, G, Esposito, G, Fiorentino, R, Chiurazzi, B, Battista, C & Panza, N 2008, 'Target therapy in metastatic renal cell carcinoma', European Journal of Cancer, Supplement, vol. 6, no. 14, pp. 38-41. https://doi.org/10.1016/j.ejcsup.2008.06.022
Cartenì, G. ; Grimaldi, A. M. ; Guida, T. ; Riccardi, F. ; Biglietto, M. ; Perrotta, E. ; Otero, M. ; De Rosa, P. ; Nicolella, G. ; Esposito, G. ; Fiorentino, R. ; Chiurazzi, B. ; Battista, C. ; Panza, N. / Target therapy in metastatic renal cell carcinoma. In: European Journal of Cancer, Supplement. 2008 ; Vol. 6, No. 14. pp. 38-41.
@article{c15ea4731a144250a817549eea7199d6,
title = "Target therapy in metastatic renal cell carcinoma",
abstract = "Metastatic RCC with 38,000 new cases diagnosed in the United States every year is notoriously resistant to conventional chemotherapy and is almost invariably an incurable condition. New biologic drugs are beginning to break this resistance, reflecting in the registration of four innovative agents for treatment of advanced RCC in the last 2 years, bevacizumab, sorafenib, sunitinib and temsirolimus. Small-molecule multikinase inhibitors targeting VEGF receptors (sunitinib and sorafenib) can prolong time to progression and preserve quality of life when used in newly diagnosed or previously treated patients. The anti-VEGF antibody bevacizumab enhances response rate and prolongs disease control when added to interferon. Temsirolimus, mammalian target of rapamycin inhibitor, prolongs the survival duration of patients with poor-risk disease. In this review, we report pre-clinical data, data relative to registrative phase III trials, and guideline indications for an optimal use of these new agents that are revolutionising the management of metastatic Renal Cell Carcinoma.",
keywords = "Renal cell carcinoma",
author = "G. Carten{\`i} and Grimaldi, {A. M.} and T. Guida and F. Riccardi and M. Biglietto and E. Perrotta and M. Otero and {De Rosa}, P. and G. Nicolella and G. Esposito and R. Fiorentino and B. Chiurazzi and C. Battista and N. Panza",
year = "2008",
month = "10",
doi = "10.1016/j.ejcsup.2008.06.022",
language = "English",
volume = "6",
pages = "38--41",
journal = "European Journal of Cancer, Supplement",
issn = "1359-6349",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - Target therapy in metastatic renal cell carcinoma

AU - Cartenì, G.

AU - Grimaldi, A. M.

AU - Guida, T.

AU - Riccardi, F.

AU - Biglietto, M.

AU - Perrotta, E.

AU - Otero, M.

AU - De Rosa, P.

AU - Nicolella, G.

AU - Esposito, G.

AU - Fiorentino, R.

AU - Chiurazzi, B.

AU - Battista, C.

AU - Panza, N.

PY - 2008/10

Y1 - 2008/10

N2 - Metastatic RCC with 38,000 new cases diagnosed in the United States every year is notoriously resistant to conventional chemotherapy and is almost invariably an incurable condition. New biologic drugs are beginning to break this resistance, reflecting in the registration of four innovative agents for treatment of advanced RCC in the last 2 years, bevacizumab, sorafenib, sunitinib and temsirolimus. Small-molecule multikinase inhibitors targeting VEGF receptors (sunitinib and sorafenib) can prolong time to progression and preserve quality of life when used in newly diagnosed or previously treated patients. The anti-VEGF antibody bevacizumab enhances response rate and prolongs disease control when added to interferon. Temsirolimus, mammalian target of rapamycin inhibitor, prolongs the survival duration of patients with poor-risk disease. In this review, we report pre-clinical data, data relative to registrative phase III trials, and guideline indications for an optimal use of these new agents that are revolutionising the management of metastatic Renal Cell Carcinoma.

AB - Metastatic RCC with 38,000 new cases diagnosed in the United States every year is notoriously resistant to conventional chemotherapy and is almost invariably an incurable condition. New biologic drugs are beginning to break this resistance, reflecting in the registration of four innovative agents for treatment of advanced RCC in the last 2 years, bevacizumab, sorafenib, sunitinib and temsirolimus. Small-molecule multikinase inhibitors targeting VEGF receptors (sunitinib and sorafenib) can prolong time to progression and preserve quality of life when used in newly diagnosed or previously treated patients. The anti-VEGF antibody bevacizumab enhances response rate and prolongs disease control when added to interferon. Temsirolimus, mammalian target of rapamycin inhibitor, prolongs the survival duration of patients with poor-risk disease. In this review, we report pre-clinical data, data relative to registrative phase III trials, and guideline indications for an optimal use of these new agents that are revolutionising the management of metastatic Renal Cell Carcinoma.

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=55649122294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649122294&partnerID=8YFLogxK

U2 - 10.1016/j.ejcsup.2008.06.022

DO - 10.1016/j.ejcsup.2008.06.022

M3 - Article

AN - SCOPUS:55649122294

VL - 6

SP - 38

EP - 41

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 1359-6349

IS - 14

ER -